FAQ on CNS Pharmaceuticals Inc.'s 1-for-12 Reverse Stock Split
Summary
What is CNS Pharmaceuticals Inc. announcing?
CNS Pharmaceuticals Inc. is announcing a 1-for-12 reverse stock split effective July 22, 2025.
Why is CNS Pharmaceuticals Inc. implementing a reverse stock split?
The reverse stock split is designed to affect all shareholders uniformly by consolidating shares and adjusting warrants and equity awards proportionally.
How will the reverse stock split work?
Each 12 shares of common stock will convert into one share, with proportional adjustments to warrants and equity awards, and no fractional shares will be issued—holders will receive cash instead.
When will the reverse stock split take effect?
The reverse stock split will take effect on July 22, 2025.
Will the stock symbol change after the reverse stock split?
No, the common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508.
What changes will be made to the authorized share count and par value?
The authorized share count will be reduced to 25 million, while the par value remains $0.001.
What is CNS Pharmaceuticals Inc.’s focus?
CNS Pharmaceuticals Inc. is a biopharma company focused on treating brain and CNS cancers, with a lead drug candidate, Berubicin, for serious brain and CNS oncology indications.
Where can I find more information about CNS Pharmaceuticals Inc.?
More information is available in the company’s newsroom at https://ibn.fm/CNSP and on their website at www.CNSPharma.com.
What is TinyGems?
TinyGems is a specialized communications platform focusing on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio @ IBN, offering various corporate communications solutions.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 108619